View ValuationKaryopharm Therapeutics 将来の成長Future 基準チェック /26Karyopharm Therapeuticsは、58.4%と43.2%でそれぞれ年率58.4%で利益と収益が成長すると予測される一方、EPSはgrowで72.8%年率。主要情報58.4%収益成長率72.82%EPS成長率Biotechs 収益成長27.2%収益成長率43.2%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日13 Aug 2026今後の成長に関する最新情報分析記事 • 10hEarnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its quarterly result this time...お知らせ • Aug 13Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. Based on its current operating plans, Karyopharm expects the following for full year 2026: Total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.Price Target Changed • Jul 22Price target increased by 12% to US$14.80Up from US$13.17, the current price target is an average from 5 analysts. New target price is 88% above last closing price of US$7.87. Stock is up 62% over the past year. The company is forecast to post a net loss per share of US$4.14 next year compared to a net loss per share of US$17.93 last year.お知らせ • May 15Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. For the year, the company expects total revenue to be in the range of $130 million to $150 million.Price Target Changed • Mar 25Price target decreased by 16% to US$12.83Down from US$15.33, the current price target is an average from 6 analysts. New target price is 146% above last closing price of US$5.21. Stock is up 7.4% over the past year. The company is forecast to post a net loss per share of US$4.90 next year compared to a net loss per share of US$17.93 last year.Breakeven Date Change • Mar 02Forecast to breakeven in 2028The 7 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2027. The company is expected to make a profit of US$25.0m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.すべての更新を表示Recent updates分析記事 • 10hEarnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its quarterly result this time...Reported Earnings • Aug 14Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: US$2.32 loss per share. Revenue: US$33.4m (down 12% from 2Q 2025). Net loss: US$67.0m (loss widened 80% from 2Q 2025). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US.お知らせ • Aug 13Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. Based on its current operating plans, Karyopharm expects the following for full year 2026: Total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.お知らせ • Aug 10Karyopharm Therapeutics Inc. to Report Q2, 2026 Results on Aug 13, 2026Karyopharm Therapeutics Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 13, 2026ナラティブ更新 • Aug 05KPTI: FDA Feedback On Myelofibrosis Will Support Bullish RepricingAnalysts have lowered the fair value estimate for Karyopharm Therapeutics from $16.00 to $11.00, reflecting reduced price targets after mixed trial updates. Myelofibrosis prospects are supported by FDA feedback, while endometrial cancer data and a recent downgrade temper overall expectations.New Risk • Aug 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$44.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-US$266m). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$64m net loss in 3 years). Market cap is less than US$100m (US$44.6m market cap).お知らせ • Jul 31+ 1 more updateKaryopharm Therapeutics Inc. Plans To Submit Supplemental New Drug Application For Selinexor Plus Ruxolitinib In Myelofibrosis Under Accelerated Approval PathwayKaryopharm Therapeutics Inc. planned to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for the treatment of patients with myelofibrosis. The planned submission followed productive engagements with the FDA, including written feedback that spleen volume reduction = 35% (SVR35) appeared to qualify as a reasonably likely surrogate endpoint (RLSE) to predict overall survival and could be used to support an sNDA under the accelerated approval pathway. The company planned to use overall survival data from long-term follow-up of the ongoing Phase 3 SENTRY trial to verify clinical benefit. Overall survival was a pre-specified secondary endpoint of SENTRY. The trial did not permit patient crossover; patients, investigators and the Karyopharm study team remained blinded to treatment assignment during ongoing follow-up. The planned sNDA would be based on results from the randomized, double-blind, Phase 3 SENTRY trial that compared selinexor in combination with ruxolitinib against placebo in combination with ruxolitinib, including the statistically significant improvement in SVR35 at week 24, the rapid, deep and sustained nature of the spleen responses, a promising overall survival signal, reductions in variant allele frequency and the overall safety data package. SENTRY (XPORT-MF-034; NCT04562389) was a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 10^9/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial were spleen volume reduction = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. The results from the Phase 3 SENTRY trial were presented at the 2026 American Society of Clinical Oncology Annual Meeting and were simultaneously published in the peer-reviewed Journal of Clinical Oncology. In addition, the results were presented at the 2026 European Hematology Association Congress, where the presentation was recognized as one of the six best abstracts at the meeting. XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high-unmet need cancer indications. XPOVIO (selinexor) is a prescription medicine approved: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (Xd). Warnings and Precautions: Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care. Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony-stimulating factors. Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care. Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care. Serious Infection: Monitor for infection and treat promptly. Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes. Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception. Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract. Adverse Reactions: The most common adverse reactions (=20%) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3-4 laboratory abnormalities (=10%) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia. In the BOSTON trial, fatal adverse reactions occurred in 6% of patients within 30 days of last treatment. Serious adverse reactions occurred in 52% of patients. Treatment discontinuation rate due to adverse reactions was 19%. The most common adverse reactions (=20%) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in 9% of patients. Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%. Use In Specific Populations: Lactation: Advise not to breastfeed.ナラティブ更新 • Jul 22KPTI: Reset Expectations And Misunderstood Compensation Plan Will Support Bullish RepricingKaryopharm Therapeutics' updated analyst price target of $16, reduced from $23, reflects a reset in fair value assumptions along with revised expectations for revenue growth, profit margins, and future P/E. Analysts point to recent stock weakness around the compensation plan as a potential misread rather than a change in the underlying story.Price Target Changed • Jul 22Price target increased by 12% to US$14.80Up from US$13.17, the current price target is an average from 5 analysts. New target price is 88% above last closing price of US$7.87. Stock is up 62% over the past year. The company is forecast to post a net loss per share of US$4.14 next year compared to a net loss per share of US$17.93 last year.Seeking Alpha • Jul 21Karyopharm Therapeutics: Balance Sheet Poor But Catalysts AheadSummary Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead. The SENTRY trial in myelofibrosis patients showed mixed results on the co-primary endpoints, but a preliminary survival benefit may strengthen with mature data. Prior SIENDO trial data in endometrial cancer revealed a potential benefit for selinexor in certain subgroups, supporting the upcoming XPORT-EC-042 readout. KPTI faces cash burn and debt concerns, but positive trial results and potential treatment guideline inclusion for selinexor in myelofibrosis could provide it with strategic options. Read the full article on Seeking Alphaナラティブ更新 • Jul 08KPTI: Elevated Expectations For 2026 Revenue Will Likely Constrain Future UpsideAnalysts have raised their fair value estimate for Karyopharm Therapeutics from $5.00 to $7.31, citing updated assumptions about discount rates, revenue growth, profit margins, and future P/E, which are reflected in recent price target increases from the Street. Analyst Commentary Recent Street research on Karyopharm Therapeutics highlights a mix of optimism around the company’s potential and caution around how that potential is reflected in the stock price.ナラティブ更新 • Jun 24KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward ProfileAnalysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.ナラティブ更新 • Jun 07KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline OpportunityAnalysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.お知らせ • Jun 03Karyopharm Therapeutics Presents Results from Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in MyelofibrosisKaryopharm Therapeutics Inc. presented the results of its Phase 3 SENTRY trial in a late-breaking oral presentation titled: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial (LBA6500) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The SENTRY results were also published in the peer-reviewed Journal of Clinical Oncology (JCO). The combination of selinexor plus ruxolitinib demonstrated a statistically significant improvement in the co-primary endpoint of spleen volume reduction of 35% or more (SVR35), with rapid, deep and sustained spleen volume reduction seen in the combination arm and a consistent benefit observed across prespecified subgroups. At week 24, SVR35 was achieved in 49.8% of patients randomized to the selinexor combination versus 28.0% of patients randomized to ruxolitinib alone (odds ratio 2.58; 95% CI [1.60 to 4.17]; p). Similar symptom improvement from baseline was observed with the selinexor combination compared to ruxolitinib alone as measured by Abs-TSS at week 24. A mean (95% CI) reduction of 9.9 points (-11.2 to -8.6) was observed in patients randomized to the selinexor combination versus a reduction of 10.9 points (-12.6 to -9.1) in patients randomized to ruxolitinib alone. Symptom reductions were consistent across each of the six domains measured. The adjusted mean difference of 0.97 points (95% CI [-1.07 to 3.02]; p=0.825) in Abs-TSS, a co-primary endpoint, did not meet statistical significance. A promising overall survival signal, a pre-specified secondary endpoint, was observed with the selinexor combination compared to ruxolitinib alone. As of February 20, 2026, 224 (95.3%) patients randomized to the selinexor combination and 106 (89.8%) randomized to ruxolitinib alone were alive. With a median follow-up of 11.6 and 12.6 months, respectively, overall survival favored the selinexor combination with a hazard ratio of 0.43 (95% CI [0.19 to 1.00]; nominal one-sided p=0.022) with separation of Kaplan–Meier curves occurring around month 9. Potential disease modification from a pre-specified exploratory endpoint was observed as early as week 24 from baseline in the combination arm. VAF reduction =20% at week 24 occurred in 32.0% of patients receiving the selinexor combination versus 23.9% of patients receiving ruxolitinib alone and correlated with SVR35 response. Circulating peripheral blasts are a poor prognostic factor and potential marker of disease burden. A post-hoc analysis showed that more patients who received the selinexor combination and who had no detectable circulating peripheral blasts at baseline maintained no detectable blasts through the course of treatment compared to patients who received ruxolitinib alone. For patients with circulating peripheral blasts at baseline, more patients who received the selinexor combination had no detectable blasts through the course of treatment compared to patients who received ruxolitinib alone. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. Treatment emergent adverse events (TEAEs) occurred in 99.1% of patients receiving the selinexor combination and in 97.4% of patients receiving ruxolitinib alone. The five most common all-grade TEAEs in the selinexor combination arm were thrombocytopenia (selinexor plus ruxolitinib arm: 59%; placebo plus ruxolitinib arm: 43%), anemia (57%; 58%), nausea (57%; 17%), constipation (32%; 36%) and neutropenia (27%; 9%) (n=234; n=116). The rate of grade 3+ TEAEs was 70% in the selinexor combination arm compared to 50% in the placebo plus ruxolitinib arm, and were primarily hematologic in nature. The percentage of patients treated with the combination who experienced TEAEs leading to death occurred in 0.9% of patients receiving the combination compared to 2.6% of patients receiving ruxolitinib alone. Confirmed leukemic transformation was 1.7% in each arm. SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in myelofibrosis and endometrial cancer. XPOVIO (selinexor) is a prescription medicine approved: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (Xd). Thrombocytopenia: Monitor platelet counts throughout treatment.Reported Earnings • May 16First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$1.02 loss per share (improved from US$2.77 loss in 1Q 2025). Revenue: US$35.1m (up 17% from 1Q 2025). Net loss: US$22.4m (loss narrowed 4.6% from 1Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • May 15Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. For the year, the company expects total revenue to be in the range of $130 million to $150 million.お知らせ • May 07Karyopharm Therapeutics Inc. to Report Q1, 2026 Results on May 14, 2026Karyopharm Therapeutics Inc. announced that they will report Q1, 2026 results on May 14, 2026ナラティブ更新 • May 03KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future UpsideAnalyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.ナラティブ更新 • Apr 19KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future ReturnsAnalysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.お知らせ • Apr 14Karyopharm Therapeutics Inc., Annual General Meeting, May 21, 2026Karyopharm Therapeutics Inc., Annual General Meeting, May 21, 2026.ナラティブ更新 • Apr 04KPTI: Funding Strains And Execution Risks Will Likely Restrain Future UpsideThe Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.Price Target Changed • Mar 25Price target decreased by 16% to US$12.83Down from US$15.33, the current price target is an average from 6 analysts. New target price is 146% above last closing price of US$5.21. Stock is up 7.4% over the past year. The company is forecast to post a net loss per share of US$4.90 next year compared to a net loss per share of US$17.93 last year.お知らせ • Mar 25Karyopharm Therapeutics Inc. announced that it expects to receive $29.999661 million in funding from RA Capital Management, L.P.Karyopharm Therapeutics Inc. entered into a securities purchase agreement with new investor RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. for issuance of 1,030,354 common shares at a price of $6.785 per share for gross proceeds of $6,990,951.89, and 3,391,164 pre-funded warrants to purchase up to 3,391,164 common shares at a purchase price of $6.7849 per pre-funded warrant for gross proceeds of $23,008,708.6236; for aggregate gross proceeds of $29,999,660.5136 on March 24, 2026. The company will also issue accompanying warrants to purchase 4,421,518 shares with an exercise price of $10 per share. The exercise price of the pre-funded warrants will be $0.0001 per share, and the pre-funded warrants will be immediately exercisable and will not expire. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about March 26, 2026. The purchaser of the securities described herein represented, among other things, that it is an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that it is acquiring such securities for investment purposes only and not with a view to any resale, distribution or other disposition of the Shares, the Pre-Funded Warrants and the Common Stock Warrants in violation of the United States federal securities laws.お知らせ • Mar 24Karyopharm Therapeutics Inc. Reports Topline Results From Phase 3 SENTRY Trial In MyelofibrosisKaryopharm Therapeutics Inc. reported topline results from its Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in frontline myelofibrosis (n=353). The trial met the first co-primary endpoint, demonstrating statistically significant improvement in spleen volume reduction of 35% or more (SVR35) for patients treated with the combination of selinexor plus ruxolitinib, with rapid, deep and sustained spleen volume reduction rates seen in the combination arm. The mean change in absolute total symptom score (Abs-TSS) at week 24 relative to baseline was comparable across the two arms with similar symptom improvement relative to baseline; the difference across the two arms was not statistically significant. The topline results suggest a promising signal in overall survival (OS) for the combination arm. Spleen Volume: 50% of patients who received the combination of selinexor plus ruxolitinib achieved a statistically significant improvement in SVR35 at week 24 compared to 28% of patients who received ruxolitinib alone (one-sided p. Symptoms: Similar symptom improvement from baseline was observed in patients who received the combination of selinexor plus ruxolitinib compared to ruxolitinib alone as measured by Abs-TSS at week 24. Patients who received the combination reported a 9.89 point improvement in Abs-TSS compared to a 10.86 point improvement in patients who received ruxolitinib alone. Overall Survival: Promising OS signal was observed in patients who received the combination of selinexor plus ruxolitinib compared to ruxolitinib alone with a hazard ratio of 0.43 (95% CI [0.19, 1.00] nominal one-sided p=0.0222). The Company intends to continue to follow OS to maturity to further evaluate this signal. Overall Survival Associated with SVR35: Post-hoc landmark analyses at weeks 12 and 24 suggest SVR35 may predict overall survival. Variant Allele Frequency (VAF) Reduction: Evidence of potential disease modification from a pre-specified exploratory endpoint was observed at week 24 from baseline in the combination arm as 32% of patients who received the combination achieved a =20% reduction in VAF for JAK2, MPL, and CALR compared to 24% of patients who received ruxolitinib alone (n=261). Other Secondary and Exploratory Endpoints: Across other secondary and exploratory endpoints of progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement, no meaningful difference was observed between the trial arms as of the data cut-off of February 20, 2026. The Company intends to further evaluate these endpoints as they mature. Patients were randomized 2:1 to 60 mg of selinexor once weekly plus ruxolitinib or placebo plus ruxolitinib. The ruxolitinib dose was determined based on the patients' baseline platelet count per the drug's prescribing information. All data presented are as of the data cut-off of February 20, 2026. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. The five most common all-grade treatment emergent adverse events (TEAEs) in the selinexor plus ruxolitinib arm were thrombocytopenia (selinexor plus ruxolitinib arm: 59%; placebo plus ruxolitinib arm: 43%), anemia (57%; 58%), nausea (57%; 17%), constipation (32%; 36%) and neutropenia (27%; 9%) (n=234; n=116). The rate of grade 3+ TEAEs was 70% in the selinexor plus ruxolitinib arm compared to 50% in the placebo plus ruxolitinib arm. The rate of TEAEs leading to treatment discontinuation was 15% in the selinexor plus ruxolitinib arm and 9% in the placebo plus ruxolitinib arm. The rate of confirmed leukemic transformations was the same across both arms of the trial at 1.7%. The Company will be meeting with the U.S. Food and Drug Administration (FDA) to discuss the totality of the data from the SENTRY trial and its supplemental new drug application (sNDA) filing plan. The Company plans to share additional data from the Phase 3 SENTRY trial at an upcoming medical meeting and expects to submit a manuscript to a peer-reviewed medical journal. The Company believes that potential inclusion in relevant compendia could occur in the second half of 2026.ナラティブ更新 • Mar 21KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline OpportunityAnalysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.New Risk • Mar 14New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$233k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$75m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$233k sold).New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$196m Forecast net loss in 3 years: US$119m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$75m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).ナラティブ更新 • Mar 07KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish RepricingAnalysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.Breakeven Date Change • Mar 02Forecast to breakeven in 2028The 7 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2027. The company is expected to make a profit of US$25.0m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.ナラティブ更新 • Feb 20KPTI: Execution And Funding Risks Will Likely Cap Bullish RepricingAnalysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.Major Estimate Revision • Feb 20Consensus EPS estimates upgraded to US$5.07 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$5.78 to -US$5.07 per share. Revenue forecast unchanged from US$139.1m at last update. Biotechs industry in the US expected to see average net income decline 7.7% next year. Consensus price target of US$15.33 unchanged from last update. Share price rose 8.2% to US$9.67 over the past week.New Risk • Feb 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$196m Forecast net loss in 3 years: US$44m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$89m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).Reported Earnings • Feb 13Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$17.93 loss per share (further deteriorated from US$9.41 loss in FY 2024). Revenue: US$146.1m (flat on FY 2024). Net loss: US$196.0m (loss widened 157% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 46%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.New Risk • Feb 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$89m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$89m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$269m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Breakeven Date Change • Feb 12No longer forecast to breakevenThe 7 analysts covering Karyopharm Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$40.5m in 2028. New consensus forecast suggests the company will make a loss of US$41.5m in 2028.お知らせ • Feb 12Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2026Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2026. For the year, the Company expects total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.ナラティブ更新 • Feb 06KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III MilestoneAnalysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.お知らせ • Feb 05Karyopharm Therapeutics Inc. to Report Q4, 2025 Results on Feb 12, 2026Karyopharm Therapeutics Inc. announced that they will report Q4, 2025 results on Feb 12, 2026ナラティブ更新 • Jan 23KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III MilestoneNarrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.お知らせ • Jan 13Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025Karyopharm Therapeutics Inc. provided earnings guidance for the fourth quarter and full year 2025. For the period, based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $33 million for the fourth quarter 2025. For the full year, based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $145 million for the full year 2025.分析記事 • Jan 11Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift SharesYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...ナラティブ更新 • Jan 09KPTI: Financing Overhangs Will Likely Outweigh MF Timeline SupportAnalysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.ナラティブ更新 • Dec 25KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution RiskAnalysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.ナラティブ更新 • Dec 11KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III ReadoutAnalysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.ナラティブ更新 • Nov 27KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III DataAnalysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.ナラティブ更新 • Nov 11KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future OpportunityKaryopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.Reported Earnings • Nov 04Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$3.82 loss per share. Revenue: US$44.0m (up 14% from 3Q 2024). Net loss: US$33.1m (loss widened 3.3% from 3Q 2024). Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 8.4%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.お知らせ • Nov 04Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year 2025Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the full year 2025. For the year, the company expects total revenue to be in the range of $140 million to $155 million.Breakeven Date Change • Nov 03Forecast to breakeven in 2027The 5 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$50.0m in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.ナラティブ更新 • Oct 28Extended Cash Runway Will Support Pivotal Phase III Clinical MilestonesKaryopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.お知らせ • Oct 27Karyopharm Therapeutics Inc. to Report Q3, 2025 Results on Nov 03, 2025Karyopharm Therapeutics Inc. announced that they will report Q3, 2025 results on Nov 03, 2025New Risk • Oct 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 92% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$239m). Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$130m net loss next year). Share price has been volatile over the past 3 months (16% average weekly change).New Risk • Oct 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$239m). Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$130m net loss next year). Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (US$51.6m market cap).ナラティブ更新 • Oct 13Phase III Trials And Global Partnerships Will Advance Personalized MedicineKaryopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.Price Target Changed • Oct 13Price target decreased by 11% to US$23.07Down from US$25.92, the current price target is an average from 7 analysts. New target price is 311% above last closing price of US$5.62. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$12.00 next year compared to a net loss per share of US$9.41 last year.Major Estimate Revision • Oct 09Consensus EPS estimates fall by 22%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$9.88 to -US$12.04 per share. Revenue forecast unchanged at US$149.5m. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target down from US$25.92 to US$24.42. Share price fell 7.5% to US$5.82 over the past week.お知らせ • Oct 08+ 1 more updateKaryopharm Therapeutics Inc. announced that it expects to receive $23.748952 million in fundingKaryopharm Therapeutics Inc. announced that it has entered into a note purchase agreement whereby the Company agreed to issue and sell in a private placement new 9.00% senior secured convertible notes due 2028 in the principal amount of $15,000,000 on October 7, 2025. The issuance and sale of the 2028 Notes is expected to close on or around the Closing Date, subject to customary closing conditions. The 2028 Notes will be senior secured second-lien obligations of the Company and bear interest at a rate of 9.00% per year payable quarterly in arrears on March 31, June 30, September 30, and December 31 of each year, beginning on December 31, 2025. Interest will be paid in kind on December 31, 2025 and March 31, 2026 with cash interest payments beginning on June 30, 2026. The 2028 Notes will mature on October 15, 2028, unless earlier converted, redeemed or repurchased in accordance with their terms. The 2028 Notes will be convertible by holders of the 2028 Notes into shares of common stock at an initial conversion rate of 150.6024 shares per $1,000 principal amount of 2028 Notes (equivalent to an initial conversion price of $6.64 per share of common stock). On the same day, the company announced that it will issue pursuant to a purchase agreement with certain Institutional Investors, an aggregate of 1,487,917 shares of common stock at a price of $5.88 and accompanying warrants to purchase 1,317,771 shares, for aggregate gross proceeds of $8,748,951.96. The warrants will have an exercise price of $6.64 exercisable until October 10, 2028. The transaction is expected to close on October 10, 2025.New Risk • Sep 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$103m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$239m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Market cap is less than US$100m (US$50.7m market cap).お知らせ • Sep 12Karyopharm Therapeutics Inc. Announces Resignation of Mansoor Raza Mirza from the Board, Effective September 8, 2025On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the Board") of Karyopharm Therapeutics Inc. (the Company"), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza's resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Dr. Mirza is also resigning from his position as Chief Oncologist at Copenhagen University National Medical Center, effective October 1, 2025, to focus his professional efforts on his new executive role in industry. In connection with Dr. Mirza's resignation, the consulting agreement between the Company and Mirza Consulting, an entity wholly-owned by Dr. Mirza, for consulting and advisory services provided to the Company by Dr. Mirza was terminated effective as of September 8, 2025.分析記事 • Sep 11Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...お知らせ • Sep 11Karyopharm Therapeutics Inc. Announces Completion of Enrollment in the Phase 3 Sentry Trial in MyelofibrosisKaryopharm Therapeutics Inc. announced the completion of enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients. The trial enrolled 353 patients and aims to assess the efficacy of this combination therapy, with top-line results anticipated in March 2026. The co-primary endpoints for this trial are spleen volume response rate = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. This trial is significant as it may lead to the first combination therapy approved for the treatment of myelofibrosis, depending on the outcome of the data.Major Estimate Revision • Aug 18Consensus EPS estimates upgraded to US$9.83 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$12.80 to -US$9.83 per share. Revenue forecast steady at US$148.3m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$29.25 to US$25.92. Share price rose 57% to US$5.92 over the past week.ナラティブ更新 • Aug 15Phase III Trials And Global Partnerships Will Advance Personalized MedicineKaryopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.分析記事 • Aug 14US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest ResultsNasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...Reported Earnings • Aug 12Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$4.32 loss per share (down from US$2.26 profit in 2Q 2024). Revenue: US$37.9m (down 11% from 2Q 2024). Net loss: US$37.3m (down 304% from profit in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.2%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.お知らせ • Aug 12Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2025Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2025. For the year, the company expects total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.お知らせ • Aug 05Karyopharm Therapeutics Inc. to Report Q2, 2025 Results on Aug 11, 2025Karyopharm Therapeutics Inc. announced that they will report Q2, 2025 results on Aug 11, 2025Major Estimate Revision • Jul 13Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$11.61 to -US$12.80 per share. Revenue forecast unchanged at US$147.1m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$28.93 unchanged from last update. Share price rose 3.6% to US$4.55 over the past week.分析記事 • May 24Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...分析記事 • May 22Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay PacketKey Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...Reported Earnings • May 14First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2025 results: US$2.77 loss per share (improved from US$4.13 loss in 1Q 2024). Revenue: US$30.0m (down 9.4% from 1Q 2024). Net loss: US$23.5m (loss narrowed 26% from 1Q 2024). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.New Risk • May 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$128m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$186m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$133m net loss in 3 years). Significant insider selling over the past 3 months (US$170k sold). Market cap is less than US$100m (US$52.7m market cap).Price Target Changed • May 13Price target decreased by 32% to US$33.07Down from US$48.64, the current price target is an average from 7 analysts. New target price is 572% above last closing price of US$4.92. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$11.61 next year compared to a net loss per share of US$9.41 last year.お知らせ • May 13Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Year 2025Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the year 2025. Based on its current operating plans, the company expects the following for full year 2025: Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.お知らせ • May 09Karyopharm Therapeutics Inc. to Report Q1, 2025 Results on May 12, 2025Karyopharm Therapeutics Inc. announced that they will report Q1, 2025 results on May 12, 2025Price Target Changed • Apr 15Price target decreased by 21% to US$38.64Down from US$48.93, the current price target is an average from 7 analysts. New target price is 807% above last closing price of US$4.26. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$14.45 next year compared to a net loss per share of US$9.41 last year.お知らせ • Apr 15Karyopharm Therapeutics Inc., Annual General Meeting, May 28, 2025Karyopharm Therapeutics Inc., Annual General Meeting, May 28, 2025.新しいナラティブ • Apr 08Phase III SENTRY And XPOVIO Approvals Will Secure Future Success Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards. New Risk • Mar 07New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$171k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$128m free cash flow). Negative equity (-US$186m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$133m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Significant insider selling over the past 3 months (US$171k sold). Market cap is less than US$100m (US$52.3m market cap).Recent Insider Transactions • Mar 07President recently sold US$74k worth of stockOn the 4th of March, Richard Paulson sold around 12k shares on-market at roughly US$6.29 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Richard has been a net seller over the last 12 months, reducing personal holdings by US$110k.Major Estimate Revision • Feb 26Consensus EPS estimates fall by 24%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$161.3m to US$148.8m. Losses expected to increase from US$11.48 per share to US$14.21. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$58.08 unchanged from last update. Share price rose 9.2% to US$9.83 over the past week.お知らせ • Feb 25Karyopharm Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select MarketKaryopharm Therapeutics Inc. announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.お知らせ • Feb 21Karyopharm Therapeutics Inc. Auditor Raises 'Going Concern' DoubtKaryopharm Therapeutics Inc. filed its 10-K on Feb 19, 2025 for the period ending Dec 31, 2024. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.Reported Earnings • Feb 19Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$0.63 loss per share (improved from US$1.25 loss in FY 2023). Revenue: US$145.2m (flat on FY 2023). Net loss: US$76.4m (loss narrowed 47% from FY 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) exceeded analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.お知らせ • Feb 19Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2025Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2025. For the year, the company expects Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. U.S. XPOVIO net product revenue to be in the range of $115 million to $130 million.お知らせ • Feb 12Karyopharm Therapeutics Inc. to Report Q4, 2024 Results on Feb 19, 2025Karyopharm Therapeutics Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 19, 2025Major Estimate Revision • Jan 17Consensus EPS estimates upgraded to US$0.64 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$152.9m to US$144.9m. 2024 losses expected to reduce from -US$0.732 to -US$0.637 per share. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$4.50 unchanged from last update. Share price fell 8.1% to US$0.66 over the past week.お知らせ • Jan 15Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024Karyopharm Therapeutics Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company expects total revenue to be approximately $30 million. For the full year, the company expects revenue to be $145 million.お知らせ • Jan 02+ 1 more updateKaryopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025Karyopharm Therapeutics Inc. announced the appointment of Lori Macomber as Chief Financial Officer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. Ms. Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies. She has a proven track record in financial management for companies ranging from start-up to Fortune 500 and has also successfully supported various collaboration partnerships, business development activities and licensing deals. Most recently, she served as Chief Financial Officer at Legend Biotech Corporation. Previously, Ms. Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer (formerly Pharmacia). Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.分析記事 • Dec 24Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price DropKaryopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...お知らせ • Dec 10Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsKaryopharm Therapeutics Inc. announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Most recently, Brendan served as Managing Director at Argot Partners where he advised biopharmaceutical companies on their investor relations and corporate communications programs. Previously, Brendan led investor relations for Tenet Healthcare and also served as Chief Financial Officer of Tenet's Massachusetts Market. Earlier in his career, he worked in the equity research department at Lehman Brothers and Barclays and also participated in a financial leadership training program at AT&T. Brendan earned an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.業績と収益の成長予測NasdaqGS:KPTI - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028316-86N/A-73412/31/2027177-115N/A-110512/31/2026136-160N/A-7966/30/2026147-225-65-65N/A3/31/2026151-195-59-59N/A12/31/2025146-196-75-75N/A9/30/2025143-125-89-89N/A6/30/2025137-124-103-103N/A3/31/2025142-68-123-123N/A12/31/2024145-76-128-127N/A9/30/2024148-87-120-120N/A6/30/2024146-90-131-130N/A3/31/2024140-141-118-118N/A12/31/2023146-143-93-93N/A9/30/2023146-140-101-101N/A6/30/2023146-142-100-100N/A3/31/2023148-158-109-109N/A12/31/2022157-165-150-150N/A9/30/2022250-88-97-97N/A6/30/2022251-104-99-93N/A3/31/2022234-108-119-113N/A12/31/2021210-124-113-107N/A9/30/2021119-206-169-163N/A6/30/2021102-208-184-184N/A3/31/2021113-201-168-168N/A12/31/2020108-196-160-160N/A9/30/202091-201-169-169N/A6/30/202083-189-161-161N/A3/31/202059-186N/A-169N/A12/31/201941-200N/A-191N/A9/30/201923-209N/A-200N/A6/30/201910-216N/A-202N/A3/31/201920-206N/A-191N/A12/31/201830-178N/A-159N/A9/30/201832-159N/A-116N/A6/30/201831-142N/A-100N/A3/31/201812-138N/A-84N/A12/31/20172-129N/A-74N/A9/30/20170-117N/A-88N/A6/30/20170-112N/A-87N/A3/31/20170-112N/A-86N/A12/31/20160-110N/A-84N/A9/30/20160-112N/A-85N/A6/30/20160-117N/A-90N/A3/31/20160-119N/A-97N/A12/31/20150-118N/A-94N/A9/30/20150-115N/A-86N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KPTI今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: KPTI今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: KPTI今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: KPTIの収益 ( 43.2% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。高い収益成長: KPTIの収益 ( 43.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KPTIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 23:34終値2026/08/14 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Karyopharm Therapeutics Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Colleen KusyBairdYing HuangBofA Global ResearchHarshita PolishettyB. Riley Securities, Inc.17 その他のアナリストを表示
分析記事 • 10hEarnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its quarterly result this time...
お知らせ • Aug 13Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. Based on its current operating plans, Karyopharm expects the following for full year 2026: Total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Price Target Changed • Jul 22Price target increased by 12% to US$14.80Up from US$13.17, the current price target is an average from 5 analysts. New target price is 88% above last closing price of US$7.87. Stock is up 62% over the past year. The company is forecast to post a net loss per share of US$4.14 next year compared to a net loss per share of US$17.93 last year.
お知らせ • May 15Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. For the year, the company expects total revenue to be in the range of $130 million to $150 million.
Price Target Changed • Mar 25Price target decreased by 16% to US$12.83Down from US$15.33, the current price target is an average from 6 analysts. New target price is 146% above last closing price of US$5.21. Stock is up 7.4% over the past year. The company is forecast to post a net loss per share of US$4.90 next year compared to a net loss per share of US$17.93 last year.
Breakeven Date Change • Mar 02Forecast to breakeven in 2028The 7 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2027. The company is expected to make a profit of US$25.0m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
分析記事 • 10hEarnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its quarterly result this time...
Reported Earnings • Aug 14Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: US$2.32 loss per share. Revenue: US$33.4m (down 12% from 2Q 2025). Net loss: US$67.0m (loss widened 80% from 2Q 2025). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US.
お知らせ • Aug 13Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. Based on its current operating plans, Karyopharm expects the following for full year 2026: Total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
お知らせ • Aug 10Karyopharm Therapeutics Inc. to Report Q2, 2026 Results on Aug 13, 2026Karyopharm Therapeutics Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 13, 2026
ナラティブ更新 • Aug 05KPTI: FDA Feedback On Myelofibrosis Will Support Bullish RepricingAnalysts have lowered the fair value estimate for Karyopharm Therapeutics from $16.00 to $11.00, reflecting reduced price targets after mixed trial updates. Myelofibrosis prospects are supported by FDA feedback, while endometrial cancer data and a recent downgrade temper overall expectations.
New Risk • Aug 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$44.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-US$266m). Shareholders have been substantially diluted in the past year (162% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$64m net loss in 3 years). Market cap is less than US$100m (US$44.6m market cap).
お知らせ • Jul 31+ 1 more updateKaryopharm Therapeutics Inc. Plans To Submit Supplemental New Drug Application For Selinexor Plus Ruxolitinib In Myelofibrosis Under Accelerated Approval PathwayKaryopharm Therapeutics Inc. planned to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for the treatment of patients with myelofibrosis. The planned submission followed productive engagements with the FDA, including written feedback that spleen volume reduction = 35% (SVR35) appeared to qualify as a reasonably likely surrogate endpoint (RLSE) to predict overall survival and could be used to support an sNDA under the accelerated approval pathway. The company planned to use overall survival data from long-term follow-up of the ongoing Phase 3 SENTRY trial to verify clinical benefit. Overall survival was a pre-specified secondary endpoint of SENTRY. The trial did not permit patient crossover; patients, investigators and the Karyopharm study team remained blinded to treatment assignment during ongoing follow-up. The planned sNDA would be based on results from the randomized, double-blind, Phase 3 SENTRY trial that compared selinexor in combination with ruxolitinib against placebo in combination with ruxolitinib, including the statistically significant improvement in SVR35 at week 24, the rapid, deep and sustained nature of the spleen responses, a promising overall survival signal, reductions in variant allele frequency and the overall safety data package. SENTRY (XPORT-MF-034; NCT04562389) was a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 10^9/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial were spleen volume reduction = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. The results from the Phase 3 SENTRY trial were presented at the 2026 American Society of Clinical Oncology Annual Meeting and were simultaneously published in the peer-reviewed Journal of Clinical Oncology. In addition, the results were presented at the 2026 European Hematology Association Congress, where the presentation was recognized as one of the six best abstracts at the meeting. XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high-unmet need cancer indications. XPOVIO (selinexor) is a prescription medicine approved: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (Xd). Warnings and Precautions: Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care. Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony-stimulating factors. Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care. Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care. Serious Infection: Monitor for infection and treat promptly. Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes. Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception. Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract. Adverse Reactions: The most common adverse reactions (=20%) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3-4 laboratory abnormalities (=10%) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia. In the BOSTON trial, fatal adverse reactions occurred in 6% of patients within 30 days of last treatment. Serious adverse reactions occurred in 52% of patients. Treatment discontinuation rate due to adverse reactions was 19%. The most common adverse reactions (=20%) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in 9% of patients. Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%. Use In Specific Populations: Lactation: Advise not to breastfeed.
ナラティブ更新 • Jul 22KPTI: Reset Expectations And Misunderstood Compensation Plan Will Support Bullish RepricingKaryopharm Therapeutics' updated analyst price target of $16, reduced from $23, reflects a reset in fair value assumptions along with revised expectations for revenue growth, profit margins, and future P/E. Analysts point to recent stock weakness around the compensation plan as a potential misread rather than a change in the underlying story.
Price Target Changed • Jul 22Price target increased by 12% to US$14.80Up from US$13.17, the current price target is an average from 5 analysts. New target price is 88% above last closing price of US$7.87. Stock is up 62% over the past year. The company is forecast to post a net loss per share of US$4.14 next year compared to a net loss per share of US$17.93 last year.
Seeking Alpha • Jul 21Karyopharm Therapeutics: Balance Sheet Poor But Catalysts AheadSummary Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead. The SENTRY trial in myelofibrosis patients showed mixed results on the co-primary endpoints, but a preliminary survival benefit may strengthen with mature data. Prior SIENDO trial data in endometrial cancer revealed a potential benefit for selinexor in certain subgroups, supporting the upcoming XPORT-EC-042 readout. KPTI faces cash burn and debt concerns, but positive trial results and potential treatment guideline inclusion for selinexor in myelofibrosis could provide it with strategic options. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 08KPTI: Elevated Expectations For 2026 Revenue Will Likely Constrain Future UpsideAnalysts have raised their fair value estimate for Karyopharm Therapeutics from $5.00 to $7.31, citing updated assumptions about discount rates, revenue growth, profit margins, and future P/E, which are reflected in recent price target increases from the Street. Analyst Commentary Recent Street research on Karyopharm Therapeutics highlights a mix of optimism around the company’s potential and caution around how that potential is reflected in the stock price.
ナラティブ更新 • Jun 24KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward ProfileAnalysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.
ナラティブ更新 • Jun 07KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline OpportunityAnalysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.
お知らせ • Jun 03Karyopharm Therapeutics Presents Results from Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in MyelofibrosisKaryopharm Therapeutics Inc. presented the results of its Phase 3 SENTRY trial in a late-breaking oral presentation titled: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial (LBA6500) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The SENTRY results were also published in the peer-reviewed Journal of Clinical Oncology (JCO). The combination of selinexor plus ruxolitinib demonstrated a statistically significant improvement in the co-primary endpoint of spleen volume reduction of 35% or more (SVR35), with rapid, deep and sustained spleen volume reduction seen in the combination arm and a consistent benefit observed across prespecified subgroups. At week 24, SVR35 was achieved in 49.8% of patients randomized to the selinexor combination versus 28.0% of patients randomized to ruxolitinib alone (odds ratio 2.58; 95% CI [1.60 to 4.17]; p). Similar symptom improvement from baseline was observed with the selinexor combination compared to ruxolitinib alone as measured by Abs-TSS at week 24. A mean (95% CI) reduction of 9.9 points (-11.2 to -8.6) was observed in patients randomized to the selinexor combination versus a reduction of 10.9 points (-12.6 to -9.1) in patients randomized to ruxolitinib alone. Symptom reductions were consistent across each of the six domains measured. The adjusted mean difference of 0.97 points (95% CI [-1.07 to 3.02]; p=0.825) in Abs-TSS, a co-primary endpoint, did not meet statistical significance. A promising overall survival signal, a pre-specified secondary endpoint, was observed with the selinexor combination compared to ruxolitinib alone. As of February 20, 2026, 224 (95.3%) patients randomized to the selinexor combination and 106 (89.8%) randomized to ruxolitinib alone were alive. With a median follow-up of 11.6 and 12.6 months, respectively, overall survival favored the selinexor combination with a hazard ratio of 0.43 (95% CI [0.19 to 1.00]; nominal one-sided p=0.022) with separation of Kaplan–Meier curves occurring around month 9. Potential disease modification from a pre-specified exploratory endpoint was observed as early as week 24 from baseline in the combination arm. VAF reduction =20% at week 24 occurred in 32.0% of patients receiving the selinexor combination versus 23.9% of patients receiving ruxolitinib alone and correlated with SVR35 response. Circulating peripheral blasts are a poor prognostic factor and potential marker of disease burden. A post-hoc analysis showed that more patients who received the selinexor combination and who had no detectable circulating peripheral blasts at baseline maintained no detectable blasts through the course of treatment compared to patients who received ruxolitinib alone. For patients with circulating peripheral blasts at baseline, more patients who received the selinexor combination had no detectable blasts through the course of treatment compared to patients who received ruxolitinib alone. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. Treatment emergent adverse events (TEAEs) occurred in 99.1% of patients receiving the selinexor combination and in 97.4% of patients receiving ruxolitinib alone. The five most common all-grade TEAEs in the selinexor combination arm were thrombocytopenia (selinexor plus ruxolitinib arm: 59%; placebo plus ruxolitinib arm: 43%), anemia (57%; 58%), nausea (57%; 17%), constipation (32%; 36%) and neutropenia (27%; 9%) (n=234; n=116). The rate of grade 3+ TEAEs was 70% in the selinexor combination arm compared to 50% in the placebo plus ruxolitinib arm, and were primarily hematologic in nature. The percentage of patients treated with the combination who experienced TEAEs leading to death occurred in 0.9% of patients receiving the combination compared to 2.6% of patients receiving ruxolitinib alone. Confirmed leukemic transformation was 1.7% in each arm. SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in myelofibrosis and endometrial cancer. XPOVIO (selinexor) is a prescription medicine approved: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (Xd). Thrombocytopenia: Monitor platelet counts throughout treatment.
Reported Earnings • May 16First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$1.02 loss per share (improved from US$2.77 loss in 1Q 2025). Revenue: US$35.1m (up 17% from 1Q 2025). Net loss: US$22.4m (loss narrowed 4.6% from 1Q 2025). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • May 15Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026Karyopharm Therapeutics Inc. reaffirmed Earnings Guidance for the Full-Year of 2026. For the year, the company expects total revenue to be in the range of $130 million to $150 million.
お知らせ • May 07Karyopharm Therapeutics Inc. to Report Q1, 2026 Results on May 14, 2026Karyopharm Therapeutics Inc. announced that they will report Q1, 2026 results on May 14, 2026
ナラティブ更新 • May 03KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future UpsideAnalyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.
ナラティブ更新 • Apr 19KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future ReturnsAnalysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.
お知らせ • Apr 14Karyopharm Therapeutics Inc., Annual General Meeting, May 21, 2026Karyopharm Therapeutics Inc., Annual General Meeting, May 21, 2026.
ナラティブ更新 • Apr 04KPTI: Funding Strains And Execution Risks Will Likely Restrain Future UpsideThe Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.
Price Target Changed • Mar 25Price target decreased by 16% to US$12.83Down from US$15.33, the current price target is an average from 6 analysts. New target price is 146% above last closing price of US$5.21. Stock is up 7.4% over the past year. The company is forecast to post a net loss per share of US$4.90 next year compared to a net loss per share of US$17.93 last year.
お知らせ • Mar 25Karyopharm Therapeutics Inc. announced that it expects to receive $29.999661 million in funding from RA Capital Management, L.P.Karyopharm Therapeutics Inc. entered into a securities purchase agreement with new investor RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. for issuance of 1,030,354 common shares at a price of $6.785 per share for gross proceeds of $6,990,951.89, and 3,391,164 pre-funded warrants to purchase up to 3,391,164 common shares at a purchase price of $6.7849 per pre-funded warrant for gross proceeds of $23,008,708.6236; for aggregate gross proceeds of $29,999,660.5136 on March 24, 2026. The company will also issue accompanying warrants to purchase 4,421,518 shares with an exercise price of $10 per share. The exercise price of the pre-funded warrants will be $0.0001 per share, and the pre-funded warrants will be immediately exercisable and will not expire. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about March 26, 2026. The purchaser of the securities described herein represented, among other things, that it is an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that it is acquiring such securities for investment purposes only and not with a view to any resale, distribution or other disposition of the Shares, the Pre-Funded Warrants and the Common Stock Warrants in violation of the United States federal securities laws.
お知らせ • Mar 24Karyopharm Therapeutics Inc. Reports Topline Results From Phase 3 SENTRY Trial In MyelofibrosisKaryopharm Therapeutics Inc. reported topline results from its Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in frontline myelofibrosis (n=353). The trial met the first co-primary endpoint, demonstrating statistically significant improvement in spleen volume reduction of 35% or more (SVR35) for patients treated with the combination of selinexor plus ruxolitinib, with rapid, deep and sustained spleen volume reduction rates seen in the combination arm. The mean change in absolute total symptom score (Abs-TSS) at week 24 relative to baseline was comparable across the two arms with similar symptom improvement relative to baseline; the difference across the two arms was not statistically significant. The topline results suggest a promising signal in overall survival (OS) for the combination arm. Spleen Volume: 50% of patients who received the combination of selinexor plus ruxolitinib achieved a statistically significant improvement in SVR35 at week 24 compared to 28% of patients who received ruxolitinib alone (one-sided p. Symptoms: Similar symptom improvement from baseline was observed in patients who received the combination of selinexor plus ruxolitinib compared to ruxolitinib alone as measured by Abs-TSS at week 24. Patients who received the combination reported a 9.89 point improvement in Abs-TSS compared to a 10.86 point improvement in patients who received ruxolitinib alone. Overall Survival: Promising OS signal was observed in patients who received the combination of selinexor plus ruxolitinib compared to ruxolitinib alone with a hazard ratio of 0.43 (95% CI [0.19, 1.00] nominal one-sided p=0.0222). The Company intends to continue to follow OS to maturity to further evaluate this signal. Overall Survival Associated with SVR35: Post-hoc landmark analyses at weeks 12 and 24 suggest SVR35 may predict overall survival. Variant Allele Frequency (VAF) Reduction: Evidence of potential disease modification from a pre-specified exploratory endpoint was observed at week 24 from baseline in the combination arm as 32% of patients who received the combination achieved a =20% reduction in VAF for JAK2, MPL, and CALR compared to 24% of patients who received ruxolitinib alone (n=261). Other Secondary and Exploratory Endpoints: Across other secondary and exploratory endpoints of progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement, no meaningful difference was observed between the trial arms as of the data cut-off of February 20, 2026. The Company intends to further evaluate these endpoints as they mature. Patients were randomized 2:1 to 60 mg of selinexor once weekly plus ruxolitinib or placebo plus ruxolitinib. The ruxolitinib dose was determined based on the patients' baseline platelet count per the drug's prescribing information. All data presented are as of the data cut-off of February 20, 2026. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. The five most common all-grade treatment emergent adverse events (TEAEs) in the selinexor plus ruxolitinib arm were thrombocytopenia (selinexor plus ruxolitinib arm: 59%; placebo plus ruxolitinib arm: 43%), anemia (57%; 58%), nausea (57%; 17%), constipation (32%; 36%) and neutropenia (27%; 9%) (n=234; n=116). The rate of grade 3+ TEAEs was 70% in the selinexor plus ruxolitinib arm compared to 50% in the placebo plus ruxolitinib arm. The rate of TEAEs leading to treatment discontinuation was 15% in the selinexor plus ruxolitinib arm and 9% in the placebo plus ruxolitinib arm. The rate of confirmed leukemic transformations was the same across both arms of the trial at 1.7%. The Company will be meeting with the U.S. Food and Drug Administration (FDA) to discuss the totality of the data from the SENTRY trial and its supplemental new drug application (sNDA) filing plan. The Company plans to share additional data from the Phase 3 SENTRY trial at an upcoming medical meeting and expects to submit a manuscript to a peer-reviewed medical journal. The Company believes that potential inclusion in relevant compendia could occur in the second half of 2026.
ナラティブ更新 • Mar 21KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline OpportunityAnalysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.
New Risk • Mar 14New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$233k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$75m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$233k sold).
New Risk • Mar 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$196m Forecast net loss in 3 years: US$119m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$75m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$119m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
ナラティブ更新 • Mar 07KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish RepricingAnalysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.
Breakeven Date Change • Mar 02Forecast to breakeven in 2028The 7 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 17% per year to 2027. The company is expected to make a profit of US$25.0m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
ナラティブ更新 • Feb 20KPTI: Execution And Funding Risks Will Likely Cap Bullish RepricingAnalysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.
Major Estimate Revision • Feb 20Consensus EPS estimates upgraded to US$5.07 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$5.78 to -US$5.07 per share. Revenue forecast unchanged from US$139.1m at last update. Biotechs industry in the US expected to see average net income decline 7.7% next year. Consensus price target of US$15.33 unchanged from last update. Share price rose 8.2% to US$9.67 over the past week.
New Risk • Feb 15New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$196m Forecast net loss in 3 years: US$44m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$89m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
Reported Earnings • Feb 13Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: US$17.93 loss per share (further deteriorated from US$9.41 loss in FY 2024). Revenue: US$146.1m (flat on FY 2024). Net loss: US$196.0m (loss widened 157% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 46%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
New Risk • Feb 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$89m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$89m free cash flow). Negative equity (-US$293m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$269m). Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Breakeven Date Change • Feb 12No longer forecast to breakevenThe 7 analysts covering Karyopharm Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$40.5m in 2028. New consensus forecast suggests the company will make a loss of US$41.5m in 2028.
お知らせ • Feb 12Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2026Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2026. For the year, the Company expects total revenue to be in the range of $130 million to $150 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
ナラティブ更新 • Feb 06KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III MilestoneAnalysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.
お知らせ • Feb 05Karyopharm Therapeutics Inc. to Report Q4, 2025 Results on Feb 12, 2026Karyopharm Therapeutics Inc. announced that they will report Q4, 2025 results on Feb 12, 2026
ナラティブ更新 • Jan 23KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III MilestoneNarrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.
お知らせ • Jan 13Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025Karyopharm Therapeutics Inc. provided earnings guidance for the fourth quarter and full year 2025. For the period, based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $33 million for the fourth quarter 2025. For the full year, based on preliminary unaudited financial information, the Company expects total revenue, which includes license and royalty revenue from partners, to be approximately $145 million for the full year 2025.
分析記事 • Jan 11Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift SharesYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...
ナラティブ更新 • Jan 09KPTI: Financing Overhangs Will Likely Outweigh MF Timeline SupportAnalysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.
ナラティブ更新 • Dec 25KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution RiskAnalysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.
ナラティブ更新 • Dec 11KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III ReadoutAnalysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.
ナラティブ更新 • Nov 27KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III DataAnalysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.
ナラティブ更新 • Nov 11KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future OpportunityKaryopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.
Reported Earnings • Nov 04Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: US$3.82 loss per share. Revenue: US$44.0m (up 14% from 3Q 2024). Net loss: US$33.1m (loss widened 3.3% from 3Q 2024). Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) missed analyst estimates by 8.4%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
お知らせ • Nov 04Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year 2025Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the full year 2025. For the year, the company expects total revenue to be in the range of $140 million to $155 million.
Breakeven Date Change • Nov 03Forecast to breakeven in 2027The 5 analysts covering Karyopharm Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$50.0m in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
ナラティブ更新 • Oct 28Extended Cash Runway Will Support Pivotal Phase III Clinical MilestonesKaryopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.
お知らせ • Oct 27Karyopharm Therapeutics Inc. to Report Q3, 2025 Results on Nov 03, 2025Karyopharm Therapeutics Inc. announced that they will report Q3, 2025 results on Nov 03, 2025
New Risk • Oct 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 92% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$239m). Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$130m net loss next year). Share price has been volatile over the past 3 months (16% average weekly change).
New Risk • Oct 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 7.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$239m). Earnings are forecast to decline by an average of 7.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$130m net loss next year). Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (US$51.6m market cap).
ナラティブ更新 • Oct 13Phase III Trials And Global Partnerships Will Advance Personalized MedicineKaryopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.
Price Target Changed • Oct 13Price target decreased by 11% to US$23.07Down from US$25.92, the current price target is an average from 7 analysts. New target price is 311% above last closing price of US$5.62. Stock is down 56% over the past year. The company is forecast to post a net loss per share of US$12.00 next year compared to a net loss per share of US$9.41 last year.
Major Estimate Revision • Oct 09Consensus EPS estimates fall by 22%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$9.88 to -US$12.04 per share. Revenue forecast unchanged at US$149.5m. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target down from US$25.92 to US$24.42. Share price fell 7.5% to US$5.82 over the past week.
お知らせ • Oct 08+ 1 more updateKaryopharm Therapeutics Inc. announced that it expects to receive $23.748952 million in fundingKaryopharm Therapeutics Inc. announced that it has entered into a note purchase agreement whereby the Company agreed to issue and sell in a private placement new 9.00% senior secured convertible notes due 2028 in the principal amount of $15,000,000 on October 7, 2025. The issuance and sale of the 2028 Notes is expected to close on or around the Closing Date, subject to customary closing conditions. The 2028 Notes will be senior secured second-lien obligations of the Company and bear interest at a rate of 9.00% per year payable quarterly in arrears on March 31, June 30, September 30, and December 31 of each year, beginning on December 31, 2025. Interest will be paid in kind on December 31, 2025 and March 31, 2026 with cash interest payments beginning on June 30, 2026. The 2028 Notes will mature on October 15, 2028, unless earlier converted, redeemed or repurchased in accordance with their terms. The 2028 Notes will be convertible by holders of the 2028 Notes into shares of common stock at an initial conversion rate of 150.6024 shares per $1,000 principal amount of 2028 Notes (equivalent to an initial conversion price of $6.64 per share of common stock). On the same day, the company announced that it will issue pursuant to a purchase agreement with certain Institutional Investors, an aggregate of 1,487,917 shares of common stock at a price of $5.88 and accompanying warrants to purchase 1,317,771 shares, for aggregate gross proceeds of $8,748,951.96. The warrants will have an exercise price of $6.64 exercisable until October 10, 2028. The transaction is expected to close on October 10, 2025.
New Risk • Sep 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$103m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$239m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$75m net loss in 3 years). Market cap is less than US$100m (US$50.7m market cap).
お知らせ • Sep 12Karyopharm Therapeutics Inc. Announces Resignation of Mansoor Raza Mirza from the Board, Effective September 8, 2025On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the Board") of Karyopharm Therapeutics Inc. (the Company"), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza's resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Dr. Mirza is also resigning from his position as Chief Oncologist at Copenhagen University National Medical Center, effective October 1, 2025, to focus his professional efforts on his new executive role in industry. In connection with Dr. Mirza's resignation, the consulting agreement between the Company and Mirza Consulting, an entity wholly-owned by Dr. Mirza, for consulting and advisory services provided to the Company by Dr. Mirza was terminated effective as of September 8, 2025.
分析記事 • Sep 11Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...
お知らせ • Sep 11Karyopharm Therapeutics Inc. Announces Completion of Enrollment in the Phase 3 Sentry Trial in MyelofibrosisKaryopharm Therapeutics Inc. announced the completion of enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients. The trial enrolled 353 patients and aims to assess the efficacy of this combination therapy, with top-line results anticipated in March 2026. The co-primary endpoints for this trial are spleen volume response rate = 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. This trial is significant as it may lead to the first combination therapy approved for the treatment of myelofibrosis, depending on the outcome of the data.
Major Estimate Revision • Aug 18Consensus EPS estimates upgraded to US$9.83 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$12.80 to -US$9.83 per share. Revenue forecast steady at US$148.3m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$29.25 to US$25.92. Share price rose 57% to US$5.92 over the past week.
ナラティブ更新 • Aug 15Phase III Trials And Global Partnerships Will Advance Personalized MedicineKaryopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.
分析記事 • Aug 14US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest ResultsNasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...
Reported Earnings • Aug 12Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$4.32 loss per share (down from US$2.26 profit in 2Q 2024). Revenue: US$37.9m (down 11% from 2Q 2024). Net loss: US$37.3m (down 304% from profit in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.2%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.
お知らせ • Aug 12Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2025Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2025. For the year, the company expects total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
お知らせ • Aug 05Karyopharm Therapeutics Inc. to Report Q2, 2025 Results on Aug 11, 2025Karyopharm Therapeutics Inc. announced that they will report Q2, 2025 results on Aug 11, 2025
Major Estimate Revision • Jul 13Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$11.61 to -US$12.80 per share. Revenue forecast unchanged at US$147.1m. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$28.93 unchanged from last update. Share price rose 3.6% to US$4.55 over the past week.
分析記事 • May 24Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...
分析記事 • May 22Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay PacketKey Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
Reported Earnings • May 14First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2025 results: US$2.77 loss per share (improved from US$4.13 loss in 1Q 2024). Revenue: US$30.0m (down 9.4% from 1Q 2024). Net loss: US$23.5m (loss narrowed 26% from 1Q 2024). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
New Risk • May 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$128m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-US$186m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$133m net loss in 3 years). Significant insider selling over the past 3 months (US$170k sold). Market cap is less than US$100m (US$52.7m market cap).
Price Target Changed • May 13Price target decreased by 32% to US$33.07Down from US$48.64, the current price target is an average from 7 analysts. New target price is 572% above last closing price of US$4.92. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$11.61 next year compared to a net loss per share of US$9.41 last year.
お知らせ • May 13Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Year 2025Karyopharm Therapeutics Inc. reaffirmed earnings guidance for the year 2025. Based on its current operating plans, the company expects the following for full year 2025: Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
お知らせ • May 09Karyopharm Therapeutics Inc. to Report Q1, 2025 Results on May 12, 2025Karyopharm Therapeutics Inc. announced that they will report Q1, 2025 results on May 12, 2025
Price Target Changed • Apr 15Price target decreased by 21% to US$38.64Down from US$48.93, the current price target is an average from 7 analysts. New target price is 807% above last closing price of US$4.26. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$14.45 next year compared to a net loss per share of US$9.41 last year.
お知らせ • Apr 15Karyopharm Therapeutics Inc., Annual General Meeting, May 28, 2025Karyopharm Therapeutics Inc., Annual General Meeting, May 28, 2025.
新しいナラティブ • Apr 08Phase III SENTRY And XPOVIO Approvals Will Secure Future Success Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.
New Risk • Mar 07New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$171k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$128m free cash flow). Negative equity (-US$186m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$133m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Significant insider selling over the past 3 months (US$171k sold). Market cap is less than US$100m (US$52.3m market cap).
Recent Insider Transactions • Mar 07President recently sold US$74k worth of stockOn the 4th of March, Richard Paulson sold around 12k shares on-market at roughly US$6.29 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Richard has been a net seller over the last 12 months, reducing personal holdings by US$110k.
Major Estimate Revision • Feb 26Consensus EPS estimates fall by 24%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$161.3m to US$148.8m. Losses expected to increase from US$11.48 per share to US$14.21. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$58.08 unchanged from last update. Share price rose 9.2% to US$9.83 over the past week.
お知らせ • Feb 25Karyopharm Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select MarketKaryopharm Therapeutics Inc. announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequently determined by the Company's Board of Directors. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
お知らせ • Feb 21Karyopharm Therapeutics Inc. Auditor Raises 'Going Concern' DoubtKaryopharm Therapeutics Inc. filed its 10-K on Feb 19, 2025 for the period ending Dec 31, 2024. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Reported Earnings • Feb 19Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: US$0.63 loss per share (improved from US$1.25 loss in FY 2023). Revenue: US$145.2m (flat on FY 2023). Net loss: US$76.4m (loss narrowed 47% from FY 2023). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) exceeded analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
お知らせ • Feb 19Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Full Year 2025Karyopharm Therapeutics Inc. provided earnings guidance for the full year 2025. For the year, the company expects Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. U.S. XPOVIO net product revenue to be in the range of $115 million to $130 million.
お知らせ • Feb 12Karyopharm Therapeutics Inc. to Report Q4, 2024 Results on Feb 19, 2025Karyopharm Therapeutics Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 19, 2025
Major Estimate Revision • Jan 17Consensus EPS estimates upgraded to US$0.64 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$152.9m to US$144.9m. 2024 losses expected to reduce from -US$0.732 to -US$0.637 per share. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$4.50 unchanged from last update. Share price fell 8.1% to US$0.66 over the past week.
お知らせ • Jan 15Karyopharm Therapeutics Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2024Karyopharm Therapeutics Inc. provided revenue guidance for the fourth quarter and full year 2024. For the quarter, the company expects total revenue to be approximately $30 million. For the full year, the company expects revenue to be $145 million.
お知らせ • Jan 02+ 1 more updateKaryopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025Karyopharm Therapeutics Inc. announced the appointment of Lori Macomber as Chief Financial Officer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. Ms. Macomber has over 20 years of diversified experience in leading growth and driving financial strategies for life science companies. She has a proven track record in financial management for companies ranging from start-up to Fortune 500 and has also successfully supported various collaboration partnerships, business development activities and licensing deals. Most recently, she served as Chief Financial Officer at Legend Biotech Corporation. Previously, Ms. Macomber held leadership roles of increasing responsibility with Ametek PDS, Cello Health, Eli Lilly and Company, and Pfizer (formerly Pharmacia). Ms. Macomber holds a Bachelor of Science in Accounting from Pennsylvania State University and is a Certified Public Accountant.
分析記事 • Dec 24Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price DropKaryopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...
お知らせ • Dec 10Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsKaryopharm Therapeutics Inc. announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Most recently, Brendan served as Managing Director at Argot Partners where he advised biopharmaceutical companies on their investor relations and corporate communications programs. Previously, Brendan led investor relations for Tenet Healthcare and also served as Chief Financial Officer of Tenet's Massachusetts Market. Earlier in his career, he worked in the equity research department at Lehman Brothers and Barclays and also participated in a financial leadership training program at AT&T. Brendan earned an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.
